Literature DB >> 17922228

Podocalyxin enhances the adherence of cells to platelets.

S Larrucea1, N Butta, R B Rodriguez, S Alonso-Martin, E G Arias-Salgado, M S Ayuso, R Parrilla.   

Abstract

Podocalyxin (PODXL) is a mucin protein of the CD34 family expressed in kidney glomerular podocytes, vascular endothelium, progenitor bone marrow and tumor cells. It is assumed that PODXL plays an anti-adherent role in kidney podocytes. CHO cells stably expressing human PODXL (CHO-PODXL) or human tumor cells (Tera-1) inherently expressing PODXL showed increased adherence to platelets. The adherence of cells was inhibited (70%) by blockers of platelet P-selectin, prevented by the soluble ectodomain of human PODXL (PODXL-Delta) or by the arginine-glycine-aspartate (RGDS) peptide and partially impeded by inhibition of integrin alphaVbeta3/alphaVbeta5, suggesting a coordinated action of P-selectin and integrins. Colocalization of platelet P-selectin and PODXL expressed on CHO cells was demonstrated by confocal immunofluorescence. No adherence to platelets was observed when PODXL was expressed in glycomutant CHO cells deficient in sialic acid.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17922228     DOI: 10.1007/s00018-007-7374-6

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  9 in total

1.  The emerging importance of α-L-fucose in human breast cancer: a review.

Authors:  Jay J Listinsky; Gene P Siegal; Catherine M Listinsky
Journal:  Am J Transl Res       Date:  2011-07-20       Impact factor: 4.060

2.  Ubiquitous yet distinct expression of podocalyxin on vascular surfaces in normal and tumor tissues in the rat.

Authors:  Jacqueline E Testa; Adrian Chrastina; Yan Li; Phil Oh; Jan E Schnitzer
Journal:  J Vasc Res       Date:  2009-01-10       Impact factor: 1.934

3.  Requirement of podocalyxin in TGF-beta induced epithelial mesenchymal transition.

Authors:  Xiaobo Meng; Peyman Ezzati; John A Wilkins
Journal:  PLoS One       Date:  2011-04-12       Impact factor: 3.240

4.  Diminished thrombogenic responses by deletion of the Podocalyxin Gene in mouse megakaryocytes.

Authors:  Miguel Pericacho; Sonia Alonso-Martín; Susana Larrucea; Consuelo González-Manchón; Darío Fernández; Inés Sánchez; Matilde S Ayuso; Roberto Parrilla
Journal:  PLoS One       Date:  2011-10-07       Impact factor: 3.240

Review 5.  Targeting Platelets for the Treatment of Cancer.

Authors:  Omar Elaskalani; Michael C Berndt; Marco Falasca; Pat Metharom
Journal:  Cancers (Basel)       Date:  2017-07-22       Impact factor: 6.639

6.  PcMab-47: Novel Antihuman Podocalyxin Monoclonal Antibody for Immunohistochemistry.

Authors:  Satoshi Ogasawara; Mika K Kaneko; Shinji Yamada; Ryusuke Honma; Takuro Nakamura; Noriko Saidoh; Miyuki Yanaka; Kanae Yoshida; Yuki Fujii; Yukinari Kato
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2017-04-06

7.  Podocalyxin-like protein is expressed in glioblastoma multiforme stem-like cells and is associated with poor outcome.

Authors:  Zev A Binder; I-Mei Siu; Charles G Eberhart; Colette Ap Rhys; Ren-Yuan Bai; Verena Staedtke; Hao Zhang; Nicolas R Smoll; Steven Piantadosi; Sara G Piccirillo; Francesco Dimeco; Jon D Weingart; Angelo Vescovi; Alessandro Olivi; Gregory J Riggins; Gary L Gallia
Journal:  PLoS One       Date:  2013-10-16       Impact factor: 3.240

Review 8.  Involvement of platelet-tumor cell interaction in immune evasion. Potential role of podocalyxin-like protein 1.

Authors:  Laura Amo; Estíbaliz Tamayo-Orbegozo; Natalia Maruri; Cristina Eguizabal; Olatz Zenarruzabeitia; Marta Riñón; Arantza Arrieta; Silvia Santos; Jorge Monge; Miguel Angel Vesga; Francisco Borrego; Susana Larrucea
Journal:  Front Oncol       Date:  2014-09-11       Impact factor: 6.244

9.  Epithelial-Mesenchymal Transition Induces Podocalyxin to Promote Extravasation via Ezrin Signaling.

Authors:  Julia Fröse; Michelle B Chen; Katie E Hebron; Ferenc Reinhardt; Cynthia Hajal; Andries Zijlstra; Roger D Kamm; Robert A Weinberg
Journal:  Cell Rep       Date:  2018-07-24       Impact factor: 9.423

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.